Loading...
XHEL
NXTMH
Market cap74mUSD
Oct 09, Last price  
9.20EUR
1D
2.11%
1Q
-6.31%
Jan 2017
-40.76%
IPO
-98.48%
Name

Nexstim Oyj

Chart & performance

D1W1MN
XHEL:NXTMH chart
P/E
116.12
P/S
6.07
EPS
0.08
Div yield, %
—
Shrs. gr., 5y
22.81%
Rev. gr., 5y
21.67%
Revenues
11m
+25.57%
3,190,4281,871,0272,210,4372,527,8702,482,6002,645,3482,672,1513,348,0864,113,9596,397,5169,526,6967,246,2848,735,36710,968,800
Net income
573k
P
0000000-6,782,638-4,121,615-832,1061,306,824-1,327,516-892,288573,200
CFO
2m
-11.44%
-3,075,500-3,983,700-7,785,200-9,608,600-7,225,300-5,402,900-6,192,500-6,681,500-2,724,700-2,610,8381,002,177-2,268,9651,881,0001,665,800

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Nexstim Plc, a medical technology enterprise, specializes in the creation and global distribution of non-invasive brain stimulation technologies, with operations spanning Finland, Europe, North America, and other international markets. Central to its offerings is the proprietary SmartFocus technology, featuring 3D navigation, which underpins its navigated transcranial magnetic stimulation (TMS) approach utilized for both therapeutic interventions and diagnostic assessments. The company provides two distinct systems: the NBT system, a navigated brain therapy solution designed for addressing major depression and chronic neuropathic pain, and the NBS system, a navigated brain stimulation device engineered for precise pre-surgical mapping of the brain's speech and motor cortices. Nexstim predominantly sells its NBS systems to academic institutions and teaching hospitals. Established in 2000, Nexstim Plc's corporate headquarters are located in Helsinki, Finland.

Key people

Mikko Karvinen
Chief Executive Officer, Member of the Management Board · since 2020
Joonas Juokslahti
Chief Financial Officer, Member of the Management Board · since 2020
Hanna Kotola
Vice President Legal, Quality and Regulatory Affairs; Member of the Management Team · since 2017
Henri Hannula
Chief Commercial Officer · since 2025
Gustaf Jarnefelt
Vice President, Research & Development; Member of the Management Team · since 2008
Jarmo Laine
Vice President, Medical Affairs, Member of the Management Team · since 2013
Martin Forss
Member of the Board · since 2019
Timo Hilden
Member of the Board · since 2021
Chairman of the Board · since 2019
Tero Weckroth
Member of the Board · since 2021
IPO date
Nov 14, 2014
Employees
37
Domiciled in
FI
Incorporated in
FI
Headquarters & legal address
Elimäenkatu 9 B
00510 HELSINKI
HELSINKI FI-00510
FI

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT